Trial Profile
Multicenter Investigation of Xanthine Oxidase Inhibitor Efficacy for CKD patients with Hyperuricemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Topiroxostat (Primary)
- Indications Hyperuricaemia
- Focus Therapeutic Use
- Acronyms MIE-CKD
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 13 Jan 2015 New trial record